CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

Background Probody® therapeutics are antibody prodrugs designed to be activated by tumor-associated proteases. This conditional activation restricts antibody binding to the tumor microenvironment, thereby minimizing ‘off-tumor’ toxicity. Here, we report the phase 1 data from the first-in-human study...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Omid Hamid, Fiona Thistlethwaite, Johanna Bendell, Ruth Plummer, Patrick A Ott, Rachel E Sanborn, Karen A Autio, Valentina Boni, Elisabeth GE de Vries, Javier Garcia-Corbacho, Daniel C Cho, Mark Stroh, Lawrence Lu
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	BMJ Publishing Group 2021-07-01
Serie:	Journal for ImmunoTherapy of Cancer
Länkar:	https://jitc.bmj.com/content/9/7/e002446.full
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!